Autus Asset Management LLC Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Autus Asset Management LLC reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 10.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 503 shares of the medical research company’s stock after selling 59 shares during the period. Autus Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $297,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of TMO. Marietta Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 4.3% in the 1st quarter. Marietta Wealth Management LLC now owns 12,912 shares of the medical research company’s stock valued at $7,626,000 after buying an additional 529 shares during the period. California State Teachers Retirement System raised its position in Thermo Fisher Scientific by 0.6% in the fourth quarter. California State Teachers Retirement System now owns 708,079 shares of the medical research company’s stock valued at $472,459,000 after purchasing an additional 4,340 shares during the period. Aries Wealth Management lifted its stake in shares of Thermo Fisher Scientific by 611.7% in the 4th quarter. Aries Wealth Management now owns 33,285 shares of the medical research company’s stock valued at $22,209,000 after purchasing an additional 28,608 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $197,400,000. Finally, Kayne Anderson Rudnick Investment Management LLC raised its holdings in Thermo Fisher Scientific by 1.1% in the 4th quarter. Kayne Anderson Rudnick Investment Management LLC now owns 24,890 shares of the medical research company’s stock valued at $16,608,000 after buying an additional 262 shares during the period. Institutional investors and hedge funds own 87.48% of the company’s stock.

Shares of NYSE TMO opened at $519.22 on Thursday. The stock’s 50-day simple moving average is $544.31 and its 200-day simple moving average is $575.26. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.10 and a current ratio of 1.56. The firm has a market capitalization of $203.25 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 1.70 and a beta of 0.83. Thermo Fisher Scientific Inc. has a fifty-two week low of $489.14 and a fifty-two week high of $672.34.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last posted its earnings results on Thursday, April 28th. The medical research company reported $7.25 EPS for the quarter, beating analysts’ consensus estimates of $6.17 by $1.08. Thermo Fisher Scientific had a net margin of 18.49% and a return on equity of 25.33%. The firm had revenue of $11.82 billion for the quarter, compared to the consensus estimate of $10.66 billion. During the same period last year, the firm posted $7.21 EPS. The company’s revenue was up 19.3% on a year-over-year basis. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 22.7 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 15th. Investors of record on Wednesday, June 15th will be given a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, June 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.23%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.26%.

In related news, COO Michel Lagarde sold 13,030 shares of the stock in a transaction on Friday, May 27th. The shares were sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the completion of the sale, the chief operating officer now owns 15,758 shares in the company, valued at approximately $8,903,900.32. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 2,181 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $562.46, for a total transaction of $1,226,725.26. Following the completion of the transaction, the chief executive officer now owns 183,373 shares in the company, valued at $103,139,977.58. The disclosure for this sale can be found here. Insiders have sold a total of 42,561 shares of company stock worth $23,557,413 in the last 90 days. 0.43% of the stock is currently owned by company insiders.

A number of equities analysts recently weighed in on TMO shares. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $605.00 to $525.00 in a research report on Monday, April 25th. StockNews.com started coverage on Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $658.92.

Thermo Fisher Scientific Profile (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories